EKF Diagnostics (EKF) Competitors

MaxCyte (LON:MXCT) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.

Which has preferable valuation & earnings, MXCT or EKF?

EKF Diagnostics has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	£57.52M	6.01	-£45.08M	-£27.29	-9.60
EKF Diagnostics	£49.91M	1.96	£4.68M	£1.07	20.47

Which has more risk & volatility, MXCT or EKF?

MaxCyte has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Is MXCT or EKF more profitable?

EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -78.37%. EKF Diagnostics' return on equity of 7.03% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-78.37%	-16.01%	-11.07%
EKF Diagnostics	9.37%	7.03%	5.27%

Do insiders & institutionals have more ownership in MXCT or EKF?

70.5% of MaxCyte shares are owned by institutional investors. Comparatively, 70.3% of EKF Diagnostics shares are owned by institutional investors. 1.5% of MaxCyte shares are owned by company insiders. Comparatively, 5.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media refer more to MXCT or EKF?

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 1.16 beat EKF Diagnostics' score of -1.04 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
EKF Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Does the MarketBeat Community prefer MXCT or EKF?

EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.

Company	Underperform	Outperform
MaxCyte	Outperform Votes 153 68.92%	Underperform Votes 69 31.08%
EKF Diagnostics	Outperform Votes 327 76.76%	Underperform Votes 99 23.24%

Summary

EKF Diagnostics beats MaxCyte on 9 of the 14 factors compared between the two stocks.